Visum Pharma Completes Nearly RMB 100 Million Series B+ Financing to Advance High-End Oral Solid Dosage Formulations

June 29, 2022Visum Pharmaceutical Co., Ltd. (hereinafter referred to as “Visum”) Announces Completion of Nearly RMB 100 Million in Series B+ Financing, led by industrial investor Hisun Pharmaceutical. The proceeds from this round of financing will be used for the continuous R&D of Visum's high-end formulations and the construction of a new cGMP-compliant workshop. The previous round was co-led by Hui Capital and Haida Investment.

Visum, established in June 2010, is a comprehensive pharmaceutical enterprise integrating R&D, manufacturing, export, and sales of high-end oral solid dosage forms, dedicated to building a premium one-stop international CDMO platform.Visum is headquartered in the Haikou High-Tech Industrial Development Zone, with two manufacturing centers, two R&D centers, and one marketing center. The company has passed the FDA’s GMP inspections with zero defects four times and the NMPA’s quality audits three times. Currently, five of its products are marketed in China or the United States, with annual exports of sustained- and controlled-release formulations exceeding 400 million tablets.

The company boasts robust R&D capabilities. Its current R&D team comprises high-level technical experts from world-renowned pharmaceutical companies and experienced domestic pharmaceutical professionals. Since its establishment, the company has successfully built several distinctive technological R&D platforms, including those for sustained- and controlled-release pellets, sustained- and controlled-release matrix tablets, and poorly soluble drugs. Leveraging these R&D and production platforms, the company has successfully developed more than 80 products. To date, over 20 products have passed formal bioequivalence (BE) studies, nearly 40 have met the criteria in pre-BE studies, and approximately 40 are in various stages of R&D.

The company has a robust quality system. The U.S. FDA certification is globally recognized as the most stringent GMP inspection. In recent years, the U.S. FDA has continuously raised quality system standards and strengthened regulatory oversight of pharmaceutical manufacturers exporting to the United States. Since January 2016,Visum Has Passed U.S. FDA PAI Inspections with “Zero Deficiencies” Four Times, while validating the strength of Visum’s quality system, it has also laid a solid quality foundation for the export and internationalization strategy of Visum’s products.

Visum Chairman Zhu Honggang“Sincere gratitude to the investors of this round for their support and trust in Visum and myself. With this financing, Visum will deepen its R&D efforts in high-end formulations, expand its product pipeline, and build a one-stop international CDMO platform compliant with cGMP standards. We will continue to uphold our core values of ‘Integrity in Conduct, Dedication to Medicine,’ adhere to the people-oriented philosophy, and strive to become a leading Chinese pharmaceutical enterprise rooted in China with a global presence.”

Yao Bing, Deputy General Manager of Haixiang Pharmaceutical, the lead investorstated: “We are deeply honored to partner with Visum, which boasts robust drug R&D capabilities and a comprehensive quality system. We wish Visum rapid growth in the future, helping more Chinese pharmaceuticals go global!”

Zhejiang Hisoar Pharmaceutical Co., Ltd. (abbreviated as: Hisoar Pharmaceutical; Stock Code: 002099), headquartered in Taizhou, Zhejiang Province, is a listed company under the Donggang Group. It primarily manufactures specialty active pharmaceutical ingredients (APIs), formulations, fine chemicals, dyes, and dye intermediates. The company is recognized as one of China’s Top 100 Innovative Pharmaceutical Industrial Enterprises, a Key High-Tech Enterprise under the National Torch Program, one of Zhejiang Province’s first batch of Integrity Demonstration Enterprises, and an Outstanding Self-operated Export Production Enterprise in Zhejiang Province. Its main products include APIs (such as antibiotics, cardiovascular agents, and hypoglycemic agents), fine chemicals, formulations, dyes, and intermediates. Dozens of its products have been registered with the U.S. FDA, obtained European CEP (COS) certificates, passed Japanese GMP certification, and complied with domestic GMP standards.